At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 94 enrolled
Drug / intervention
Exenatide +2 moredrug
Likely dose
Moxifloxacin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Exenatide, Moxifloxacin, and 1 other intervention for Healthy Subjects. Completed, enrolled 94 participants across 2 sites.
Detailed Summary
Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionApr 2011
Study CompletionMay 2011
TodayJul 2026
First PostedFeb 16, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.4 years ago
Interventions
Exenatidedrug
IV Exenatide (therapeutic and supratherapeutic concentrations)
Moxifloxacindrug
Oral Moxifloxacin (400 mg)
Placebo comparatordrug
IV Placebo (matching volume of placebo)